Pharma supply chain teams rarely lack SOPs; what they lack are the tools to execute those SOPs at speed and scale. This panel brings together two perspectives from opposite ends of the specialty pharma lifecycle: a preclinical-stage biotech advancing engineered T cell (CAR-T) therapies, and a commercial-stage cell and gene therapy manufacturer focused on scaling patient access. Together, they will examine how AI voice and text agents are closing the gap between documented SOPs and what actually happens when an exception, such as a cold chain excursion or a delayed clinical shipment, occurs in the field.